Nonasthmatic Eosinophilic Bronchitis: Definition, Diagnosis, and Treatment
What is NAEB?
Nonasthmatic eosinophilic bronchitis (NAEB) is a corticosteroid-responsive chronic cough condition characterized by eosinophilic airway inflammation WITHOUT the variable airflow obstruction or airway hyperresponsiveness that defines asthma 1. This condition accounts for 10-30% of chronic cough cases referred for specialist evaluation 2, 1.
Key Distinguishing Features
NAEB differs from asthma primarily in:
- Normal spirometry with no evidence of airflow obstruction
- Normal airway hyperresponsiveness (methacholine PC20 >16 mg/mL)
- Presence of sputum eosinophilia (≥3% non-squamous cells)
- Isolated chronic cough without wheeze or dyspnea 1
The pathophysiologic difference lies in mast cell localization: in NAEB, mast cells infiltrate the bronchial epithelium, whereas in asthma they infiltrate the airway smooth muscle, explaining why NAEB patients don't develop bronchospasm 1.
Diagnostic Algorithm
Step 1: Clinical Screening
Look for chronic cough (≥8 weeks duration) in a nonsmoker without:
- Wheeze or dyspnea
- Overt radiologic evidence of lung disease
- Response to bronchodilators 1
Step 2: Exclude Other Causes
Perform:
- Chest radiograph (must be normal)
- Spirometry (must show normal lung function)
- Methacholine challenge test (must be negative, PC20 >16 mg/mL) 1
Step 3: Confirm Eosinophilic Inflammation
The gold standard is induced sputum analysis showing ≥3% eosinophils 1.
Sputum induction protocol:
- Pre-medicate with short-acting bronchodilator
- Inhale hypertonic saline (3%, 4%, 5%) sequentially for 5 minutes each via ultrasonic nebulizer
- Process same-day for cell count (requires specialized lab capability) 1
Alternative if sputum induction unavailable or unsuccessful:
- Bronchial wash fluid at bronchoscopy provides similar information 1
- Elevated fractional exhaled nitric oxide (FeNO) supports the diagnosis but is not diagnostic alone 1
Step 4: Confirm Diagnosis with Treatment Response
Diagnosis is confirmed by improvement in cough following corticosteroid therapy combined with documented eosinophilia 1.
Treatment Algorithm
First-Line Treatment: Inhaled Corticosteroids
Start inhaled corticosteroids (ICS) as first-choice treatment 2. The 2020 CHEST guideline gives this a Grade 2B recommendation.
Practical approach based on evidence:
- Initial dose: Budesonide 400 μg twice daily (or equivalent ICS) 1
- Duration: Treat for at least 2-4 months to minimize relapse 2, 3
Critical caveat: A randomized trial showed that 1-month treatment resulted in 41.9% relapse rate versus only 12% with 3-month treatment at 1-year follow-up 3. The 2-month group showed intermediate results (20% relapse). Therefore, treat for a minimum of 2 months, preferably 3-4 months, to reduce recurrence risk.
Second-Line Treatment: Step-Up Therapy
If response to ICS is incomplete after 2-4 weeks, escalate treatment 2:
- Increase ICS dose (e.g., double the dose)
- Add leukotriene receptor antagonist (e.g., montelukast) 2
- Reconsider alternative causes of cough before escalating further
Important note: The 2020 CHEST guideline rates this as Grade 2C (weak recommendation) due to limited trial data 2.
Third-Line Treatment: Oral Corticosteroids
For persistent or refractory cases:
- Oral prednisone may be required, occasionally long-term 1
- No specific dosing guidelines exist; use clinical judgment based on asthma treatment principles
Emerging Therapies
Anti-IL-5 biologics (e.g., mepolizumab, benralizumab) show promise for refractory NAEB, though evidence is limited 4. Consider in patients requiring chronic oral steroids or with frequent relapses.
Common Pitfalls and Caveats
Pitfall #1: Missing the diagnosis
- NAEB is often misdiagnosed as asthma if patients receive empiric corticosteroids and improve, without objective testing for airflow obstruction or hyperresponsiveness 1
- Always perform spirometry and methacholine challenge before labeling as asthma
Pitfall #2: Inadequate treatment duration
- Stopping ICS too early (e.g., after 1 month) leads to high relapse rates 3
- Treat for minimum 2-4 months initially
Pitfall #3: Multiple causes of cough
- NAEB frequently coexists with other causes of chronic cough (post-nasal drip, GERD) 1
- Consider NAEB even when another cause is identified if response to treatment is incomplete
Pitfall #4: Occupational/allergen exposure
- Like asthma, NAEB can be triggered by occupational sensitizers or common allergens 2, 1
- Always inquire about workplace exposures and consider avoidance strategies
Natural History and Prognosis
The condition can be:
- Transient (self-limiting)
- Episodic (recurrent)
- Persistent (chronic without treatment) 1
While generally benign, some patients may develop:
- Classic asthma (progression occurs in some cases) 2
- Chronic airflow obstruction (rare) 5
- Requirement for long-term oral corticosteroids 1
Response to treatment is generally excellent when eosinophilic inflammation is present and adequately treated 1, 5.